NO974257L - Immunomodulerende preparater fra galle for behandling av immunsystemsykdommer - Google Patents

Immunomodulerende preparater fra galle for behandling av immunsystemsykdommer

Info

Publication number
NO974257L
NO974257L NO974257A NO974257A NO974257L NO 974257 L NO974257 L NO 974257L NO 974257 A NO974257 A NO 974257A NO 974257 A NO974257 A NO 974257A NO 974257 L NO974257 L NO 974257L
Authority
NO
Norway
Prior art keywords
treatment
immunomodulatory
immunomodulator
preparation
immune system
Prior art date
Application number
NO974257A
Other languages
English (en)
Other versions
NO974257D0 (no
Inventor
Paul B Percheson
Romeo Rang
Original Assignee
Imutec Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imutec Pharma Inc filed Critical Imutec Pharma Inc
Publication of NO974257D0 publication Critical patent/NO974257D0/no
Publication of NO974257L publication Critical patent/NO974257L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/413—Gall bladder; Bile
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse gjelder et preparat for anvendelse som en immunomodulator som omfatter lav- molekylvektsbestanddeler på mindre enn 3 000 dalton, med følgende egenskaper: a) kan ekstraheres fra dyregalle, b) kan stimulere monocytter og makro- fager in vitro og in vlvo, c) kan modu- lere produksjonen av tumornekrosefak- tor, d) inneholder ikke målbare mengder av IL-la, IL-ip, TNF, lL-6, IL-8, IL-4, GM-CSF eller IFN-y, e) har antiproli- ferasjonsvirkning i en ondartet muse- hybridomcellelinje, f) viser ingen cytotoksisitet overfor mononukleære celler fra humant, perifert blod eller lymfocytter, og (g) er ikke et endotok- sin. Oppfinnelsen gjelder også en frem- gangsmåte for fremstilling av prepar- atet, dets anvendelse som en irmtiuno- modulator og dets anvendelse i behand- ling av sykdommer og tilstander med en immunologisk komponent, f.eks. cancer eller endometriose.
NO974257A 1995-03-16 1997-09-15 Immunomodulerende preparater fra galle for behandling av immunsystemsykdommer NO974257L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40493295A 1995-03-16 1995-03-16
PCT/CA1996/000152 WO1996028175A1 (en) 1995-03-16 1996-03-13 Immunomodulating compositions from bile for the treatment of immune system disorders

Publications (2)

Publication Number Publication Date
NO974257D0 NO974257D0 (no) 1997-09-15
NO974257L true NO974257L (no) 1997-11-17

Family

ID=23601619

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974257A NO974257L (no) 1995-03-16 1997-09-15 Immunomodulerende preparater fra galle for behandling av immunsystemsykdommer

Country Status (11)

Country Link
US (1) US6596319B2 (no)
EP (1) EP0814821A1 (no)
JP (1) JPH11501634A (no)
KR (1) KR19980703088A (no)
CN (1) CN1182368A (no)
AU (1) AU711294B2 (no)
BR (1) BR9607967A (no)
CA (1) CA2215339C (no)
NO (1) NO974257L (no)
NZ (1) NZ302638A (no)
WO (1) WO1996028175A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040101569A1 (en) * 1996-05-16 2004-05-27 Lorus Therapeutics Inc. Immunomodulating compositions from bile
CA2206047A1 (en) * 1997-05-23 1998-11-23 Romeo Rang (Deceased) Immunomodulating compositions for the treatment of viral disorders
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
WO1999063105A1 (de) * 1998-06-03 1999-12-09 Deutsches Krebsforschungszentrum Stiffung Des Öffentlichen Rechts Glycosyl-inosit-phospho-ceramide (gipc), verfahren zu ihrer herstellung sowie ihre verwendung
WO2002038164A1 (en) * 2000-11-08 2002-05-16 Lorus Therapeutics Inc. Combination preparation of a biological response modifier and an anticancer agent and uses thereof
WO2002102363A1 (en) * 2001-06-20 2002-12-27 Lorus Therapeutics Inc. Biological response modifier composition and uses thereof
WO2005016954A2 (en) * 2003-08-14 2005-02-24 Boston Medical Center Corporation Immunologic activity measure(s) for t “helper” on-associated conditions
US7136936B2 (en) * 2003-10-03 2006-11-14 Asoka Usa Corporation Method and system for virtual powerline local area networks
US7457885B2 (en) * 2005-02-10 2008-11-25 Asoka Usa Corporation Powerline communication system and method using coupler design for additional users
US20050220912A1 (en) * 2004-03-30 2005-10-06 Theoharides Theoharis C Anti-inflammatory composition for treating pelvic endometriosis
EP1863520B1 (en) 2005-03-08 2014-12-31 Aptose Biosciences Inc. Use of interleukin 17e for the treatment of cancer
WO2008085963A1 (en) * 2007-01-05 2008-07-17 University Of Florida Research Foundation, Inc. Materials and methods for the detection, prevention and treatment of autoimmune disease
US8042027B1 (en) 2007-01-16 2011-10-18 Marvell International Ltd. BM/LLR computation for multi-dimensional TCM/BCM
US8236354B1 (en) 2012-02-17 2012-08-07 ZOR Pharmaceuticals, LLC Use of immunomodulators for the treatment of cancer
US8338383B1 (en) 2012-02-17 2012-12-25 Gregory Jr Daniel Tyree Use of immunomodulators for the treatment of cancer
CL2014003632A1 (es) * 2014-12-31 2015-06-26 Pontificia Universidad Católica De Chile Método que comprende el cultivo y expansión de células presentes en líquido ascítico de origen peritoneal, pleural, lavado peritoneal o lavados sistémicos que permite determinar el mejor tratamiento para pacientes con cáncer.
CN113143936B (zh) * 2021-02-10 2022-03-25 北京蕴汇医药科技有限公司 鹅去氧胆酸或其衍生物在制备egfr和/或stat3的抑制剂中的用途
CN114657125B (zh) * 2022-04-29 2023-08-08 中国科学院海洋研究所 鲨鱼单个核细胞的分离方法、鲨鱼稀释液及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB337797A (en) 1929-07-08 1930-11-10 Henry Leitner A specific for cancer
GB2046092B (en) 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
US4562179A (en) 1982-04-19 1985-12-31 Fujisawa Pharmaceutical Co., Ltd. Phospholipid derivatives, and pharmaceutical composition of the same
US4585762A (en) 1982-07-30 1986-04-29 Fujisawa Pharmaceutical Co., Ltd. Phospholipid derivatives, processes for use thereof and pharmaceutical composition of the same
JPS5984824A (ja) 1982-11-08 1984-05-16 Takeda Chem Ind Ltd 抗腫瘍剤
US4879226A (en) 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
US4767610A (en) 1984-10-19 1988-08-30 The Regents Of The University Of California Method for detecting abnormal cell masses in animals
US4916249A (en) 1985-07-03 1990-04-10 Hans Brachwitz Glycero-3(2)-phospho-L-serine derivatives and salts thereof
IE59777B1 (en) 1985-12-04 1994-04-06 Max Planck Gesellschaft Medicaments
GB8706313D0 (en) 1987-03-17 1987-04-23 Health Lab Service Board Treatment & prevention of viral infections
US5087721A (en) 1987-10-23 1992-02-11 The University Of Michigan Radioiodinated phosphate esters
US4965391A (en) 1987-10-23 1990-10-23 The University Of Michigan Radioiodinated phospholipid ether analogues
US5138067A (en) 1987-12-17 1992-08-11 Shionogi & Co. Ltd. Lipid derivatives
EP0356765A3 (en) 1988-08-19 1991-08-07 Takeda Chemical Industries, Ltd. Carboxylic acid derivatives, their production and use
EP0378763A1 (en) 1988-10-27 1990-07-25 Takeda Chemical Industries, Ltd. Lipids, their production and use
GB8909022D0 (en) 1989-04-20 1989-06-07 Cortecs Ltd Pharmaceutical compositions
US5109118A (en) 1989-07-06 1992-04-28 Yutaka Mizushima Modified biologically active proteins
GB8928580D0 (en) 1989-12-19 1990-02-21 Scras 3-(n-methyl-n-alkylamino)-methoxymethyl-propanol phosphocholine derivatives
US5369097A (en) 1991-04-25 1994-11-29 The University Of British Columbia Phosphonates as anti-cancer agents
US5352682A (en) * 1993-03-08 1994-10-04 Digestive Care Inc. Compositions containing salts of bile acid-aminosalicylate conjugates
ES2207639T3 (es) * 1993-09-09 2004-06-01 Lorus Therapeutics Inc. Composiciones modulares inmunologicas a partir de las bilis.
TW342436B (en) 1996-08-14 1998-10-11 Nippon Oxygen Co Ltd Combustion type harm removal apparatus (1)

Also Published As

Publication number Publication date
CA2215339C (en) 1999-01-19
NZ302638A (en) 2001-04-27
AU4873996A (en) 1996-10-02
AU711294B2 (en) 1999-10-07
CN1182368A (zh) 1998-05-20
EP0814821A1 (en) 1998-01-07
WO1996028175A1 (en) 1996-09-19
JPH11501634A (ja) 1999-02-09
KR19980703088A (ko) 1998-09-05
CA2215339A1 (en) 1996-09-19
US6596319B2 (en) 2003-07-22
NO974257D0 (no) 1997-09-15
BR9607967A (pt) 1998-01-13
US20010009680A1 (en) 2001-07-26

Similar Documents

Publication Publication Date Title
NO974257L (no) Immunomodulerende preparater fra galle for behandling av immunsystemsykdommer
Kirnbauer et al. IFN-beta 2, B cell differentiation factor 2, or hybridoma growth factor (IL-6) is expressed and released by human epidermal cells and epidermoid carcinoma cell lines.
Cheever et al. Anti-IL-4 treatment of Schistosoma mansoni-infected mice inhibits development of T cells and non-B, non-T cells expressing Th2 cytokines while decreasing egg-induced hepatic fibrosis.
Bartoccioni et al. Constitutive and cytokine-induced production of interleukin-6 by human myoblasts
Levine et al. Tumor necrosis factor-alpha induces mucin hypersecretion and MUC-2 gene expression by human airway epithelial cells.
Ichimura et al. Augmentation of interleukin 1 and interleukin 2 production by OK-432
JP4050317B2 (ja) Ｉｌ−１０含有医薬組成物
Ying et al. Ganoderma atrum polysaccharide ameliorates intestinal mucosal dysfunction associated with autophagy in immunosuppressed mice
NO960907L (no) Immunomoduleringssammensetninger fra galle
DE69431620D1 (de) Zusammensetzungen für die anwendung in menschlicher therapie, charakterisiert durch die assoziation eines muramylpeptids mit einem cytokin
Herman et al. Defective interleukin-1 production by monocytes from patients with malignant disease: interferon increases IL-1 production
Gately Interleukin-12: a recently discovered cytokine with potential for enhancing cell-mediated immune responses to tumors
EP2797609B1 (en) Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, immunoglobulins and chemotactic factors
Moor et al. Treatment with 8-MOP and UVA enhances MHC class I synthesis in RMA cells: preliminary results
Endo et al. Macrophages can produce factors capable of inducing histidine decarboxylase, a histamine-forming enzyme, in vivo in the liver, spleen, and lung of mice
Matsushima et al. Purification of human interleukin 1 from human monocyte culture supernatants and identity of thymocyte comitogenic factor, fibroblast-proliferation factor, acute-phase protein-inducing factor, and endogenous pyrogen
Fukui et al. Production of inteleukin 6 by human spleen cells stimulated with streptococcal preparation OK-432
Tamatani et al. Existence of both IL-1 alpha and beta in normal human amniotic fluid: unique high molecular weight form of IL-1 beta.
Kapp et al. Granulocyte-activating mediators (GRAM) II. Generation by human epidermal cells-relation to GM-CSF
König et al. Respiratory syncytial virus G‐protein modulates cytokine release from human peripheral blood mononuclear cells
Kitano et al. Synthesis of the third component of complement (C3) by human gastric cancer-derived cell lines
Makino et al. Increased serum levels of Th2-type cytokines and eotaxin in fibrillar-type dermatitis herpetiformis
Reiter et al. A possible role for interferon-α and activated natural killer cells in remission of AIDS-related kaposi's sarcoma: in vitro studies
JP2001058950A (ja) サイトカイン調節剤
Nagler et al. Major salivary gland dysfunction in patients with hematological malignancies receiving interleukin-2-based immunotherapy post-autologous blood stem cell transplantation (ABSCT)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application